E2B per Month
| Month |
E2B |
| Feb 2025 | 512 |
|---|
| Mar 2025 | 116 |
|---|
| Apr 2025 | 75 |
|---|
| Jul 2024 | 1 |
|---|
| Aug 2024 | 1 |
|---|
| Sep 2024 | 1 |
|---|
| Oct 2024 | 1 |
|---|
| Dec 2024 | 2 |
|---|
E2B per Company
| Company |
E2B |
| Glaxosmithkline | 394 |
|---|
| HALEON | 45 |
|---|
| Novartis Pharma AG | 36 |
|---|
| TAKEDA | 21 |
|---|
| NOVARTIS PHARMA | 18 |
|---|
| JNJFOC | 18 |
|---|
| Boehringer Ingelheim | 17 |
|---|
| AstraZeneca | 15 |
|---|
| Sanofi | 13 |
|---|
| CIPLA | 12 |
|---|
| Pfizer Inc | 11 |
|---|
| Norvatis Pharma | 9 |
|---|
| GLENMARK PHARMACEUTICALS | 8 |
|---|
| Phillips | 7 |
|---|
| CIPLA LTD | 7 |
|---|
| BAYER | 6 |
|---|
| BoehringerIngelheim | 5 |
|---|
| ROCHE | 5 |
|---|
| GlaxoSmithKlin | 5 |
|---|
| Ethypharm | 4 |
|---|
| JNJ | 4 |
|---|
| UNIVERSAL CORPORATION LIMITED | 4 |
|---|
| Pfizer | 3 |
|---|
| Gilead Pharmaceuticals Ltd | 3 |
|---|
| AZPRODSE0 | 3 |
|---|
| ABBVIE | 3 |
|---|
| GlaxoSmithKlineds | 2 |
|---|
| Novartis | 2 |
|---|
| OPELLA | 2 |
|---|
| GSK | 2 |
|---|
| VIIV HEALTHCARE LIMITED | 2 |
|---|
| Macleods Pharmaceuticals Ltd | 2 |
|---|
| SAVPROD | 2 |
|---|
| TH-VIIV HEALTHCARE LIMITED | 2 |
|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD | 2 |
|---|
| ACINO | 1 |
|---|
| TORRENT | 1 |
|---|
| 95743049 | 1 |
|---|
| Glenmark Pharmaceuticals Kenya Ltd | 1 |
|---|
| GILEAD | 1 |
|---|
| 1 |
|---|
| B|Braun Medical Kenya Ltd | 1 |
|---|
| NJFOC | 1 |
|---|
| GB-VIIV HEALTHCARE LIMITED | 1 |
|---|
| Abbott GmbH | 1 |
|---|
| Merck Healthcare KGaA | 1 |
|---|
| MACLEODS PHARMA | 1 |
|---|
| KE-VIIV HEALTHCARE LIMITED | 1 |
|---|
| PFIZERINC | 1 |
|---|
| SAAVPROD | 1 |
|---|
